Fulcrum Therapeutics Reports Stronger Than Expected Q1 Earnings
Fulcrum Therapeutics (NASDAQ:FULC) shares rose in pre-market trading after the company's first-quarter results exceeded analyst expectations. The firm reported a smaller-than-anticipated loss of $0.25 per share and highlighted positive clinical data for its drug pociredir, which could lead to a registration-enabling trial in 2026.
Tickers: $FULC
Topics: Biopharmaceutical Industry Clinical Trials Earnings Stock Price Movement